Hodgkin Lymphoma - VJHemOnc

Chemotherapy: the backbone of lymphoma treatment

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

ASH press briefing rundown: optimizing pediatric care

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

EHA 2020 Top Picks

VJHemOnc are excited to present late-breaking abstracts and key trial updates announced at this year’s virtual EHA meeting!

Brentuximab vedotin may hold improved outcomes in frontline stage III/IV classical Hodgkin lymphoma

Updated results from the ECHELON-1 study (NCT01712490) suggest the combination of brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) may…

The REAL classification of lymphoma

Twenty-five years ago, almost to the day, there was a paradigm shift in the classification of lymphoma.

features: Hodgkin Lymphoma